|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||46.12 - 47.98|
|52 Week Range||6.78 - 53.98|
|Beta (5Y Monthly)||2.98|
|PE Ratio (TTM)||779.83|
|Earnings Date||Feb 24, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.71|
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Joe Mara, Chief Financial Officer, will present the latest company overview at the H.C. Wainwright Virtual Global Life Sciences Conference. The conference is being conducted in a virtual format and a webcast of the presentation will become available on Tuesday, March 9, 2021, at 7:00 a.m. Eastern Time. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com. Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved. Investor Contact:Eric Burnsir@vcel.com+1 617-588-5666
Welcome to Vericel's fourth-quarter 2020 conference call to discuss our financial results and business highlights. Before we begin, let me remind you that on today's call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1995.
Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 25.00% year over year to $0.25, which beat the estimate of $0.20. Revenue of $45,229,000 up by 14.82% year over year, which beat the estimate of $45,000,000. Outlook The upcoming fiscal year's revenue expected to be between $161,000,000 and $164,000,000. Conference Call Details Date: Feb 24, 2021 View more earnings on VCEL Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/zxxjppat Price Action 52-week high: $53.98 52-week low: $6.78 Price action over last quarter: Up 112.90% Company Overview Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 24, 2021Stocks That Hit 52-Week Highs On Tuesday© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.